Ani Pharmaceuticals (ANIP) closed at $67.41 on November 6, 2026, down 3.2% from the previous close, on volume of 551,402 shares (30-day average 355,822).
Data as of November 6, 2026.
6-Nov-2026
ANI Pharmaceuticals (ANIP) Receives a Hold from Canaccord Genuity
TipRanks (Fri, 6-Nov 9:24 AM ET)
TipRanks (Fri, 6-Nov 9:01 AM ET)
ANI Pharmaceuticals Announces Proposed Acquisition of Egetis Therapeutics
TipRanks (Thu, 5-Nov 6:21 PM ET)
ANI Pharmaceuticals Reports Strong Third-Quarter Results, Expands Rare Disease Portfolio
TipRanks (Thu, 5-Nov 7:19 AM ET)
ANI Pharmaceuticals beats top-line and bottom-line estimates; narrows FY26 outlook
Seeking Alpha News (Thu, 5-Nov 6:55 AM ET)
ANI Pharma to buy Swedish biotech Egetis for $560M
Seeking Alpha News (Thu, 5-Nov 6:51 AM ET)
ANI Pharmaceuticals Reports Third Quarter 2026 Financial Results
Globe Newswire (Thu, 5-Nov 6:51 AM ET)
Globe Newswire (Thu, 5-Nov 6:50 AM ET)
Globe Newswire (Thu, 5-Nov 1:33 AM ET)
Here are the major earnings before the open Thursday
Seeking Alpha News (Wed, 4-Nov 6:00 PM ET)
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.
Ani Pharmaceuticals trades on the NASDAQ stock market under the symbol ANIP.
As of November 6, 2026, ANIP stock price declined to $67.41 with 551,402 million shares trading.
ANIP has a beta of 0.53, meaning it tends to be less sensitive to market movements. ANIP has a correlation of 0.05 to the broad based SPY ETF.
ANIP has a market cap of $1.55 billion. This is considered a Small Cap stock.
Last quarter Ani Pharmaceuticals reported $291 million in Revenue and $2.70 earnings per share. This beat revenue expectation by $11 million and exceeded earnings estimates by $.60.
In the last 3 years, ANIP traded as high as $99.50 and as low as $48.20.
The top ETF exchange traded funds that ANIP belongs to (by Net Assets): IJR, AVUV, VTI, IWM, PJP.
ANIP has underperformed the market in the last year with a price return of -27.2% while the SPY ETF gained +9.6%. ANIP has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -15.6% and -8.6%, respectively, while the SPY returned -4.2% and -3.8%, respectively.
ANIP support price is $68.31 and resistance is $70.94 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ANIP shares will trade within this expected range on the day.